Anticancer agent 314

Anticancer agent 314 (Compound 13n) potently inhibits the recombinant human tumor-associated carbonic anhydrase isoforms hCA IX (K_i = 27.1 nM) and hCA XII (K_i = 20.9 nM)^[1].
Anticancer agent 314 (1.5-100 μM) potently inhibits cell-free tubulin polymerization with an IC₅₀ of 6.35 μM^[1].
Anticancer agent 314 (0.01-100 μM) exhibits broad-spectrum antiproliferative activity across the NCI-60 human tumor cell line panel, with GI₅₀ values ranging from 2.48 to 31.00 μM^[1].
Anticancer agent 314 has low cytotoxicity against WI-38 normal human lung fibroblasts, with an IC₅₀ of 68.62 μM^[1].
Anticancer agent 314 (6.35 μM; 24 h) potently arrests MCF-7 human breast cancer cells in the G2/M phase of the cell cycle, increasing the G2/M population to 31.97%^[1].
Anticancer agent 314 (6.35 μM; 24 h) induces robust apoptosis in MCF-7 human breast cancer cells, increasing the total apoptotic population to 24.68%^[1].
Anticancer agent 314 (6.35 μM; 24 h) activates the p53-dependent apoptotic pathway in MCF-7 human breast cancer cells, increasing p53, Bax, and activated caspase-7 levels while reducing Bcl-2 levels^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.